Intelligencia AI
Predict drug success with AI, but relies on comprehensive data inputs.
At a glance
4.0 out of 5
Scored by Alex after real useOur verdict
Intelligencia AI helps make informed decisions in drug development. But it requires high-quality, detailed input data for accurate predictions.
✓What it does well
✕Where it falls short
Key features
Questions about Intelligencia AI
What does Intelligencia AI do?
Intelligencia AI uses AI to predict drug success and help pharma companies make informed decisions in drug development. Its Portfolio Optimizer supports internal risk identification, Dynamic Benchmarks standardize risk evaluation across portfolios, and it monitors and validates clinical programs in real time. It also surfaces insights from industry conferences and publications.
How accurate is Intelligencia AI?
The reviewer cites high prospective accuracy of over 80% for Intelligencia AI, compared with retrospective-only analyses of AI models. Its data quality is controlled by biomedical professionals, and its explainable AI gives transparency into PTRS predictions across hundreds of dimensions. Accurate predictions depend on comprehensive, precise input data.
How much does Intelligencia AI cost?
Intelligencia AI does not publish prices. Its Portfolio Optimizer, Dynamic Benchmarks and Data & Insights offerings are all priced on contact, and Toolio found no paid plan on the vendor's site in September 2026. Pricing is available by contacting the vendor.
What does Intelligencia AI need to work well?
Intelligencia AI requires comprehensive, high-quality and detailed input data for accurate predictions, and the reviewer notes such data can be expensive. It may not provide custom-built, in-house datasets for all therapeutic areas, so Toolio says it is not for teams needing datasets for niche therapeutic areas.
What platforms does Intelligencia AI run on?
Intelligencia AI runs on the web, macOS and Windows. Toolio names pharma companies looking to de-risk clinical development as its best fit, and Alex scored it 4.0 out of 5 after real use, on 5 Oct 2026.